Trial Profile
A prospective case series of Ranibizumab for the treatment of inflammatory and idiopathic choroidal neovascular membranes.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Jul 2019
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Choroidal neovascularisation
- Focus Therapeutic Use
- 31 May 2017 New trial record